Meloxicam

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 10, 2002, Pages 1501-1512

  Fleischmann, Roy ^a   Iqbal, Imran ^a   Slobodin, Gleb ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Arthritis; Cyclooxygenase inhibitors; Meloxicam; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LITHIUM; MELOXICAM; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROSTANOID; ROFECOXIB; WARFARIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; EDEMA; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GUINEA PIG; HUMAN; HYPERTENSION; INFLAMMATORY CELL; INTESTINE OBSTRUCTION; KIDNEY DISEASE; MALE; META ANALYSIS; NONHUMAN; OSTEOARTHRITIS; PROTEIN SYNTHESIS INHIBITION; RHEUMATOID ARTHRITIS; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DRUG INTERACTIONS; HUMANS; OSTEOARTHRITIS; PAIN; PRODUCT SURVEILLANCE, POSTMARKETING; SPONDYLITIS, ANKYLOSING; THIAZINES; THIAZOLES;

EID: 0036796331     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.10.1501     Document Type: Article

References (68)

1. LAWRENCE RC, HELMICK CG, ARNETT FC et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. (1998) 41:778-799
2. HEDNER T, EVERTS B: The early clinical history of salicylates in rheumatology and pain. Clin. Rheumatol. (1998) 17:17-25.
3. EVERTS B, WÄHRBORG P, HEDNER T: Cox-2 specific inhibitors the emergence of a new class of analgesics and anti inflammatory drugs. Clin. Rheumatol (2000) 19:331-334.
4. SINGH G: Recent considerations in non steroidal anti-inflammatory drug gastropathy. Am. J. Med. (1998) 105:31S-38S
5. SINGH G, TRIADAFILOPOULOS G: Epidemiology of NSAID induced gastrointestinal complications. J. Rheumatol. (1999) 26(Suppl. 56):18-24.
6. SMALLEY WE, GRIFFIN MR, FOUGHT RL et al.: Excess costs from gastrointestinal disease associated with n on steroidal anti-inflammatory drugs. J. Gen. Intern. Med. (1996) 11:461-469.
7. WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of non steroidal anti-inflammatory drugs. N. Engl. J. Med. (1999) 340:1888-1899.
8. VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action of aspirin like drugs. Nat. New Biol. (1971) 231:232-235.
9. VANE JR, BAKHLE YS, BOTTING RM: Cyclooxgenase 1 and 2. Ann. Rev. Pharmacol. Toxicol. (1998) 38:97-120.
10. WARNER TD, GIULIANO F, VOJNOVIC I et al.: Nonsteroidal drug selectivities for cyclo-oxygenase 1 rather than cyclo-oxygenase 2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA (1999) 96(13):7563-7568.
11. FITZGERALD G A, PATRONO C: The Coxibs, selective inhibitors of cyclooxgenase-2. N. Engl. J. Med. (2001) 345(6):433-442.
12. EVERTS B, WAHRBORG P, HEDNER T: COX 2 specific inhibitors the emergence of a new class of analgesic and anti-inflammatory drugs. Clin. Rheumatol. (2000) 19:331-343.
13. RICHARDSON CE, EMERY P: New cyclo-oxygenase and cytokine inhibitors. (1995) 9(4):731-758.
14. HECKEN A V, SCHWARTZ J I, DEPRE M et al.: Comparative Inhibitory activity of Rofecoxib, Meloxicam, diclofenac, Ibuprofen and Naproxen on COX2 versus COX1 in healthy volunteers. J. Clin. Pharmacol. (2000) 40:1109-1120.
15. DEQUEKER J, DEGNER F: Editorial. Inflamm. Res. (2001) 50(Suppl. 1):S3-S4.
16. ENGELHARDT G: Pharmacology of Meloxicam, a new non-steroidal anti-inflammatory drug with improved safety profile through preferential inhibition of COX-2. Br. J. Rheumatol. (1996) 35(Suppl. 1):4-12.
17. ENGELHARDT G, HOMMA D, SCHLEGEL K et al.: Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm. Res. (1995) 44:423-433.
18. ENGELHARDT G, BOGEL R, SCHNITZLER C et al.: Meloxicam: Influence on Arachidonic Acid Metabolism Part I in vitro findings. Biochem. Pharmacol (1996) 51:21-28.
19. ENGELHARDT G, BOGEL R, SCHNITZLER C et al.: Meloxicam: Influence on Arachidonic acid metabolism, part II, in vivo findings. Biochem. Pharmacol. (1996) 51:29-38.
20. PANARA M R, RENDA G, SCIULLI GS et al.: Dose dependent inhibition of platelet cyclooxgenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J. Pharmacol. Exp. Ther. (1999) 290:276-280.
21. TÜRCK D, BUSCH U, HEINZEL G et al.: Clinical pharmacokinetics of meloxicam. Eur. J. Rheumatol. Inflamm. (1996) 15:23-30.
22. TÜRCK D, ROTH W, BUSCH U: A review of the clinical pharmacokinetics of meloxicam. Br. J Rheumatol. (1996) 35(Suppl. 1):13-16.
23. Meloxicam package insert.
24. NARJES H, TÜRCK D, BUSCH U et al.: Pharmacokinetics and tolerability of meloxicam after i.m. administration. Br. J. Clin. Pharmacol. (1996) 41:135-139.
25. DEGNER F, HEINZEL G, BUSCH U. Transynovial kinetics of meloxicam. Scand. J Rheumatol. (1994) (Suppl. 98). Abstract: 121.
26. HÜBNER G, SANDER O, DEGNER F et al.: Lack of pharmacokinetic interaction of meloxicam with Methotrexate in patients with RA. J. Rheumatol. (1997) 24(5):845-851.
27. BUSCH U, HEINZEL G, NARJES H et al.: Investigation of interaction of meloxicam with cimetidine, Maalox or aspirin. J. Clin. Pharmacol. (1996) 36(1):79-84.
28. MÜLLER FO, SCHALL R, DEVAAL AC et al.: Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers. Eur. J. Clin. Pharmacol. (1995) 48:247-251.
29. TÜRCK D, HEINZEL G, LUIK G: Steady state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam. Br. J. Clin. Pharmacol. (2000) 50:197-204.
30. TÜRCK D, SU CA, HEINZEL G et al.: Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur. J. Clin. Pharmacol. (1997) 51(5): 421-425.
31. BUSCH U, HEINZEL G, NARJES H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID), in man. Eur. J. Clin. Pharmacol. (1995) 48:269-272.
32. YOCUM D, FLEISCHMANN R, DALGIN P et al.: Safety and efficacy of meloxicam in the treatment of osteoarthritis. Arch. Intern. Med. (2000) 160:2947-2954.
33. NIKAS SN, KITAS G, KARAMAOUNAS N et al.: Meloxicam induced erythema multiforme. Am. J. Med. (1999) 107(5):532-534.
34. CARRABA M, PARESCE E, ANGELINI M, GALANTI A, MARINI MG, CIGARINI P: A comparison of the local tolerability, safety and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicenter study. Curr. Med. Res. Opin. (1995) 13:343-355.
35. HOSIE J, DISTEL M, BLUHMKI E: Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclophenac sodium. Br. J. Rheumatol. (1996) 35(Suppl. 1):39-43.
36. LINDEN B, DISTEL M, BLUHMKI E: A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br. J. Rheumatol. (1996) 35(Suppl. 1):35-38.
37. HOSIE J, DISTEL M, BLUHMKI E: Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee: a six-month double-blind study. Clin. Drug. Invest. (1997) 13:175-184.
38. GOEI THE HS, LUND B, DISTEL MR, BLUHMKI E: A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage (1997) 5:283-288.
39. LUND B, DISTEL M, BLUHMKI E: A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam, treatment in patients with osteoarthritis of the knee. Scand. J. Rheumatol (1998) 27:32-37.
40. HAWKEY C, KAHAN A, STEINBRUCK K et al.: Gastrointestinal tolerability of meloxicam compared to diclophenac in osteoarthritis patients. Br. J. Rheumatol. (1998) 37:937-945.
41. DEQUEKER J, HAWKEY C, KAHAN A et al.: Improvement in gastrointestinal tolerability of the selective cyclo-oxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large scale evaluation of COX-inhibiting therapies (Select) trial in osteoarthritis. Br. J. Rheumatol. (1998) 37:946-951.
42. VALAT JP, ACCARDO S, REGINSTER J-Y et al.: A comparison of the efficacy and tolerability of meloxicam and diclophenac in the treatment of patients with osteoarthritis of the lumbar spine. Inflamm. Res. (2001) 50(Suppl.1):S30-S34.
43. LEMMEL E-M, BOLTEN W, BURGOS-VARGAS R et al.: Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J. Rheumatol. (1997) 24:282-290.
44. WOJTULEWSKI JA, SCHATTENKIRCHNER M, BARCELO P et al.: A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br. J. Rheumatol. (1996) 35(Suppl. 1):22-28.
45. HUSKISSON EC, GHOZLAN R, KURTHEN R, DEGNER FL, BLUHMKI E: A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br. J. Rheumatol. (1996) 35(Suppl. 1):29-34.
46. FOELDVARI I, BURGOS-VARGAS R, THON A, TUERCK D: High response rate in the Phase I/II study of meloxicam in juvenile rheumatoid arthritis. J. Rheumatol. (2002) 29:1079-1083.
47. HUSKISSON EC, NARJES H, BLUHMKI E: Efficacy and tolerance of meloxicam, a new NSAID, in daily oral doses of 15, 30, and 60 mg in comparison to 20 mg piroxicam in patients with rheumatoid arthritis. Scan. J. Rheumatol. (1994) (Suppl.98). Abstract: 115.
48. REGINSTER JY, DISTEL M, BLUHMKI E: A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br. J. Rheumatol. (1996) 35(Suppl.1):17-21.
49. FURST D, KOLBA K, FLEISCHMANN R et al.: Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double-blind, dose response study versus placebo and diclophenac. J. Rheumatol. (2002) 29:436-446.
50. FLEISCHMANN R, ROSZKO O, HALL D. How important if flare in the design of NSAID trials in the treatment of rheumatoid arthritis (RA)? Journal of Rheumatology (2001) 28(Suppl. 63). Abstract: W129.
51. DOUGADOS M, GUEGUEN A, NAKACHE J-P et al.: Ankylosing Spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (1999) 38:235-244.
52. AUVINET B, ZILLER R, APPELBOOM T, VELICITAT P: Comparison of the onset and intensity of action of intramuscular meloxicam in patients with acute sciatica. Clin. Ther. (1995) 17:1078-1090.
53. COLBERG K, HETTICH M, SIGMUND R, DEGNER FL: The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. Curr. Med. Res. Opin. (1996) 13:363-373.
54. BOSCH HC, SIGMUND R, HETTISH M: Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: a comparison with intramuscular and oral piroxicam. Curr. Med. Res. Opin. (1997) 14:29-38.
55. DRESER R-L, LE PARC JM, VELICITAT P, LLEU PL: Oral meloxicam is effective in acute sciatica: two randomized, double-blind trials versus placebo or diclofenac. Inflam. Res. (2001) 50(Suppl.1):S17-S23.
56. VIDAL L, KNEER W, BATURONE M, SIGMUND R: Meloxicam in acute episodes of soft-tissue rheumatism of the shoulder. Inflam. Res. (2001) 50(Suppl.1):S24-S29.
57. DISTEL M, MUELLER C, BLUHMKI E, FRIES J: Safety of meloxicam: a global analysis of clinical trials. Br. J. Rheumatol. (1996) 35(Suppl. 1):68-77.
58. SCHOENFELD P: Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am. J. Med (1999) 107(6A):48S-54S.
59. CHANG D-M, YIUNG T-H, HSU C-T, KUO S-Y, HSIEH T-C: Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis. Clin. Rheumatol. (2001) 20:104-113.
60. PATOIA I, SANTUCCI L, FURNO P et al.: A 4-week double-blind, parallel group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br. J. Rheumatol (1996) 35(Suppl.1):61-67.
61. LIPSCOMB GR, WALLIS N, ARMSTRONG G, REES WDW: Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study. Br. J. Clin. (1998) 46:133-137.
62. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N. Engl. J. Med. 2000 Nov. 23; 343:1520-1528.
63. SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus non steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13; 284(10):1247-1255.
64. STICHTENOTH DO, WAGNER B, FROLICH JC: Effect of selective inhibition of the inducible cyclo-oxygenase on rennin release in health volunteers. J. Invest. Med. (1998) 46:290-296.
65. BEVIS PJR, BIRD HA, LAPHAM G: An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br. J. Rheumatol. (1996) 35(Suppl.1):55-60.
66. DEGNER FM SIGMUND R, ZEIDLER H: Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Cin. Ther. (2000) 22:400-410.
67. MARTIN RM, BISWAS P, MANN RD: The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br. J. Clin. Pharmacol (2000) 50:35-42.
68. BARNER A. Review of clinical trials and benefits/risk ratio of meloxicam. Scand. J. Rheumatol. (1996) 25(Suppl.102):29-37.